SEC	Form	4
-----	------	---

Γ

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Check this box if no longer subject to
L	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
1	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Dermata Therapeutics, Inc.</u> [ DRMA ]		ationship of Reporting Pers all applicable)	on(s) to Issuer 10% Owner
(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/04/2024	x	Officer (give title below)	Other (specify below)
92130	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	Form filed by One Rep	,
(Zip)				
	92130 (Zip)	(Middle) 3. Date of Earliest Transaction (Month/Day/Year)   01/04/2024   2   4. If Amendment, Date of Original Filed (Month/Day/Year)   92130   (Zip)	(Middle) 3. Date of Earliest Transaction (Month/Day/Year) X   2 01/04/2024 X   92130 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indix   (Zip) (Zip) 1	Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director   2 3. Date of Earliest Transaction (Month/Day/Year) 2.   4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing   Y Y   92130 92130

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Ac Disposed Of (D		4 and 5)	Securities Beneficially Owned Following Reported	(Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$0.6099	01/04/2024		Α		50,000		(1)	01/03/2034	Common Stock	50,000	\$ <mark>0</mark>	50,000	D	

## Explanation of Responses:

1. The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.

/s/ Gerald T. Proehl, Attorney-in-01/05/2024 Fact Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.